Who We Are

GA²LEN is a Network of Excellence of the leading European clinical and research facilities in the field of allergology and asthma, associated with the European Academy of Allergy and Clinical Immunology (EAACI) and the organisation representing European patients with allergies and asthma (EFA). Started under the European Union Sixth Framework Programme for Research, GA²LEN has become a model project in Europe. GA²LEN addresses the growing public health concern of allergic diseases.

Research teams were chosen for their scientific excellence, their record on multidisciplinary working and international collaboration, and their educational activities. Since the launch of the Network, it has grown to include an additional 50 collaborating centres making GA²LEN one of the largest multidisciplinary networks of researchers in allergy and asthma worldwide.

Prof. Dr. med. Dr. h.c. Torsten Zuberbier, GA²LEN Secretary General

Integrating European research

Europe has produced some of the most important recent findings on allergy and asthma, but research tends to be fragmented in different institutes and even in different departments of the same organisation. Findings are not always shared nor rapidly translated into changes in practice. The GA²LEN Network of Excellence (NoE) exists to help integrate research activities in Europe and to establish the structure for a European Research Area of excellence in allergy and asthma that will endure.

The network aims to accelerate the application of research results into clinical practice, to meet the needs of the patients, and to help guide policy development. GA²LEN also aims to promote training and greater integration between public and private sectors in this medical field.

Uniting all interested parties, partners, and collaboration centres in decreasing the burden of allergies across Europe.
European societies
Collaboration centres
Research institutes
Small/medium enterprises

Looking for a publication?

Over 500 papers were produced by GA²LEN members – find them here.